CEO Emma Walmsley’s 40-bln-pound 2031 sales target looks fanciful after another disappointing drug trial. A healthy balance ...

The inhaler, with an older propellant, is already approved in Europe for the treatment of adults with chronic obstructive ...

The European Union has approved GSK's drug Blenrep to treat relapsed or treatment-resistant forms of a cancer affecting blood ...

The combinations are also approved for relapsed or refractory multiple myeloma in Japan, the UK and other markets including ...

The Cambridge site of an international biotechnology company will cease manufacturing, leaving 150 people without a job.

GSK is taking to the airwaves to get the message out about respiratory syncytial virus (RSV), presenting a TV special about ...

GSK sponsors 2025 National Senior Games as part of Sideline RSV campaign to raise awareness of RSV in older adults ...

GSK (GSK) stock in focus as the company secures EU approval for Blenrep combo therapies targeting the blood cancer multiple ...

A global biopharmaceutical company headquartered in London announced the layoffs of 150 Massachusetts employees last week.

In an import contrast to events in the USA, UK pharma major GSK late Thursday announced the approval of Blenrep (belantamab ...

GSK’s share price has fallen a lot in 10 months, which means it could be a huge bargain. I ran the key numbers and examined ...

GSK’s Blenrep (belantamab mafodotin) combinations have been approved by the European Commission (EC) to treat adults with relapsed or refractory multiple myeloma.